Navigation Links
Financial Results for Full Year 2008: NicOx in a Unique Position to Deliver Significant Shareholder Value
Date:2/26/2009

n revenues: - EUR0.3 million corresponding to the initial payment of EUR5.0 million from Pfizer, as a technology exclusivity fee, following the March 2006 agreement that granted Pfizer rights to apply NicOx' proprietary technology in a drug discovery research program covering the field of ophthalmology - EUR2.5 million corresponding to the funding of the research collaboration, pursuant to the above referenced agreement signed with Pfizer in March 2006 - EUR0.6 million corresponding to the balance of the spreading of the initial payment of EUR9.2 million received from Merck following the signature of a collaboration agreement for new antihypertensive drug candidates in March 2006

These amounts initially recorded as prepaid income were deferred over the estimated duration of NicOx' involvement in the research and development programs provided for under the terms of the corresponding agreements. The terms surrounding the duration of NicOx' involvement in these programs are revised periodically, if necessary.

Operating expenses

In 2008, operating expenses amounted to EUR86.4 million, compared to EUR61.8 million in 2007 (adjusted to reflect the reclassification of the research tax credit subsidies into other income as indicated below). During 2008, operating expenses were 87% attributable to research and development expenses and 13% attributable to selling and administrative expenses, compared to 82% and 18% respectively in 2007.

Research and development expenses reached EUR75.0 million in 2008, compared to EUR50.4 million in 2007 (including EUR0.8 million allocated to cost of sales in 2008 and EUR2.2 million in 2007). This significant increase in research and development expenses results mainly from the costs related to the phase 3 development of naproxcinod, such as expenses associated with contract research or
'/>"/>

SOURCE NicOx
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related biology technology :

1. Arpida Announces Full Year 2008 Financial Results
2. Nektar Therapeutics Reports Fourth Quarter and Year-End 2008 Financial Results
3. ViroPharma Incorporated Reports Fourth Quarter and Full Year 2008 Financial Results
4. American Oriental Bioengineering, Inc. to Report Fourth Quarter and Full Year 2008 Financial Results on March 9, 2009
5. Frontage Laboratories Continues to Grow Its China Business and Add Corporate Financial, Regulatory and Clinical Pharmacology Talent
6. InterMune to Release Fourth Quarter, Full Year 2008 Financial Results on February 26
7. CV Therapeutics Reports 2008 Fourth Quarter and Full Year Financial Results
8. Human Genome Sciences to Sponsor Conference Call to Discuss Full Year 2008 Financial Results
9. Adolor Corporation to Host Investor Conference Call to Report 2008 Financials and Provide an Update on the Launch of ENTEREG(R) (alvimopan)
10. BioMarin Announces Fourth Quarter and Full Year 2008 Financial Results
11. Senesco Technologies Reports Second Quarter Fiscal 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)...   Intrexon Corporation (NYSE: XON ) ... quarter 2015 financial results after the market closes on ... host a conference call at 5:30 PM ET to ... The conference call may be accessed by ... to join the "Intrexon Corporation Call."  Participants may also ...
(Date:7/31/2015)... , July 31, 2015 In ... resources that help them drive positive health outcomes, ... vital source of patient care in their communities. ... annual tradeshow and conference, AmerisourceBergen announced a new ... Pharmacy Services Administration Organization and help independent pharmacies ...
(Date:7/30/2015)... (PRWEB) , ... July 31, 2015 , ... Ralco is ... Center at the Lyon County Fair to be held August 5-9 in Marshall. The ... where their meals come from and how agriculture impacts their daily lives. This unique ...
(Date:7/30/2015)... Texas (PRWEB) , ... July 30, 2015 , ... The ... and in-depth study on the current state of the global Propanol market with a ... Sinopec, CNPC, BASF, Eastman, Dow, Carboclor, Mitsui Chemicals, Oxea, ISU Chemical, Sanofi, Royal Dutch ...
Breaking Biology Technology:Intrexon to Announce First Half and Second Quarter 2015 Financial Results and Host Conference Call on August 10th 2AmerisourceBergen Unveils Suite of Enhanced Capabilities for Independent Pharmacies at ThoughtSpot 2015 2AmerisourceBergen Unveils Suite of Enhanced Capabilities for Independent Pharmacies at ThoughtSpot 2015 3Ralco Announces Primary Sponsorship of Ralco Enrichment Center at Lyon County Fair 2Global Propanol Market Technical Data and Manufacturing Analysis 2020 2Global Propanol Market Technical Data and Manufacturing Analysis 2020 3
... (Nasdaq: BIOD ) today announced that Dr. ... present a corporate update at the 29th Annual JPMorgan ... a.m. Pacific Time (12:30 p.m. Eastern Time). The update ... formulations of its lead product, Linjeta™, including milestones and ...
... SAN DIEGO, Jan. 6, 2011 Ardea Biosciences, Inc. ... top-line results from its Phase 2b study of RDEA594 ... the treatment of gout, allopurinol.  Allopurinol currently accounts for ... gout prescription medications; however, in controlled trials, only 30-40% ...
... Mass., Jan. 6, 2011 GENFIT (Alternext: ALGFT; ISIN: ... discovery and development, focusing on the early diagnosis and ... its presence at two U.S. events: the 28th J.P. ... and the Biotech Showcase (from January 10th to 12th, ...
Cached Biology Technology:Ardea Biosciences Announces Positive Top-Line Results from Phase 2b Combination Study of RDEA594 in Allopurinol-Refractory Gout Patients 2Ardea Biosciences Announces Positive Top-Line Results from Phase 2b Combination Study of RDEA594 in Allopurinol-Refractory Gout Patients 3Ardea Biosciences Announces Positive Top-Line Results from Phase 2b Combination Study of RDEA594 in Allopurinol-Refractory Gout Patients 4Ardea Biosciences Announces Positive Top-Line Results from Phase 2b Combination Study of RDEA594 in Allopurinol-Refractory Gout Patients 5Ardea Biosciences Announces Positive Top-Line Results from Phase 2b Combination Study of RDEA594 in Allopurinol-Refractory Gout Patients 6Ardea Biosciences Announces Positive Top-Line Results from Phase 2b Combination Study of RDEA594 in Allopurinol-Refractory Gout Patients 7GENFIT: Strong U.S. Exposure for Its Biomarker Activity 2GENFIT: Strong U.S. Exposure for Its Biomarker Activity 3
(Date:7/31/2015)... -- Den 10. internationale konference om Genomik (ICG-10, ... 25. oktober i Shenzhen , Kina. ... år. Siden starten i 2006 er ICB blevet en ... er en af de mest dynamiske, entusiastiske og sjove ... gennembrud og fremskridt inden for ,omik,-forskning, som yderligere vil ...
(Date:7/31/2015)... China , 31 de julio de 2015 /PRNewswire/ ... Genómica (ICG-10,  www.icg-10.org ) del 22 al 25 de ... . La conferencia celebra su décimo aniversario ... ha convertido en una de las reuniones anuales más ... y es una de las conferencias científicas más dinámicas, ...
(Date:7/31/2015)... de 2015 A 10 a. Conferência ... pela BGI de 22-25 de outubro de 2015, em ... conferência está celebrando seu 10 o. aniversário este ano. ... uma das reuniões mais influentes do mundo no ramo ... entusiastas e prazerosos. A ICG-10 se ...
Breaking Biology News(10 mins):Den 10. internationale konference om Genomics (ICG-10) åbner i oktober 2La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 2La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 3A 10a. Conferência Internacional sobre Genômica (ICG-10) será em outubro 2A 10a. Conferência Internacional sobre Genômica (ICG-10) será em outubro 3
... Nearly 50% of couples who were interviewed at least 3 ... their surplus, stored embryos for stem cell research, according to ... April 26, 2007, advanced online publication of Cell Stem Cell, ... International Society for Stem Cell Research. , The key ...
... MIT Media Lab have invented a way to reversibly ... the prospect of controlling the haywire neuron activity that ... , Such diseases often must be treated by removing ... lead to the development of optical brain prosthetics to ...
... Dick at Ontario Cancer Institute (OCI) have developed a method ... stem cells. The converted cells, when transplanted into special mice ... entire disease process from the very moment it begins. The ... Dick, Senior Scientist at OCI, the research arm of Princess ...
Cached Biology News:Many couples choose to donate surplus embryos for stem cell research 2MIT: Pulsing light silences overactive neurons 2Cancer scientists create 'human' leukemia process to map how disease begins, progresses 2
The DNA DipStick Kit is ideal for estimating nucleic acid concentrations and approximate yields. Works with ss- and ds-DNA, RNA, and oligonucleotides at concentrations as low as 0.1 ng/l....
IHC detection kit for PCNA in cells and tissues...
Request Info...
... Synthetic peptide derived from the C-terminal ... Specificity: Reacts with the human ... Human Mouse (positive controls: WNT1-transfected HEK293 ... and mouse Mouse-1 cell lysates). ...
Biology Products: